Distribution of Reported StarClose SE Vascular Closure Device Complications in the Manufacturer and User Facility Device Experience Database

作者：Johnson D Thor^*; Durack Jeremy C; Fidelman Nicholas; Kerlan Robert K; LaBerge Jeanne M

来源：Journal of Vascular and Interventional Radiology, 2013, 24(7): 1051-1056.

DOI：10.1016/j.jvir.2013.03.032

Purpose:. TO evaluate the type and frequency of complications associated with the Star Close SE vascular closure device reported to the U.S. Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database for comparison with complications reported in clinical trials.
Materials and Methods: Complications reported in the MAUDE database related to use of the Star Close SE vascular closure device were reviewed. Keyword searches by device and manufacturer were performed for a 16-month period from July 2009 October 2010. Reports were analyzed according to complication type, frequency, and resolution, if specified. These data were compared with data on Star Close SE device complications, which included three prospective randomized trials and five prospective nonrandomized trials.
Results: Keyword searches returned 1,107 total records and 1,118 categorizable Star Close SE device complications from the 16-month MAUDE database reporting period.. Complications in order of frequency (absolute number and relative frequency, respectively) included failure to achieve hemostasis (409, 36.6%), inability to complete the deployment sequence (268, 24.0%), entrapped deployment device (224, 20%), clip not deployed (151,13.5%), late bleeding or oozing from dermatotomy site (25, 2.2%), vessel occlusion (19, 1.7%), retroperitoneal hematoma (12, 1.1%), pseudoaneurysm formation (6, 0.5%) and death (4, 0.4%). The distribution of complications differed appreciably from the combined adverse events compiled from the published trials evaluating the Star Close SE device. There were no records describing inability to remove the deployment device in the published trials, whereas this represented the third most common complication reported to the MAUDE database. Bleeding or oozing from the dermatotomy site, the most frequent relative complication reported in the published literature (53.4%), represented 2.2% of the total complications reported to the MAUDE database.
Conclusions: The type and frequency of complications reported in the MAUDE database on the StarClose SE vascular closure device differ from those published in clinical trials both in relative distribution and in type. Although these differences may reflect in Part repotting biases, the distribution of complications reported to the MAUDE database may represent useful information in the use of this device.

• 出版日期2013-7